Roniel Cabrera, M.D., M.S.
Medical Director Of Liver Transplant, Section Chief Of Hepatology & Associate Professor
Department:
MD-GASTROENTERLOGY-LIVER
Business Phone:
(352) 273-9400
Business Email:
rcabrera@ufl.edu
About Roniel Cabrera
My name is Roniel Cabrera, MD, MS, and I am an associate professor of medicine in the division of gastroenterology, hepatology and nutrition, and serve as the hepatology section chief and medical director of liver transplantation for the division. I joined the University of Florida faculty in 2006. My clinical interests include liver transplant, liver disease, cirrhosis, autoimmune hepatitis, hepatitis B and hepatitis C.
I earned my medical degree from Howard University in Washington, D.C. and completed an internal medicine residency, gastroenterology fellowship and advanced hepatology and liver transplantation fellowship at UF. I earned a Certificate in Clinical/Translational Science through participation in the UF Advanced Postgraduate Program in Clinical Investigation (APPCI), funded by a Clinical Research Curriculum Award.
I am a recipient of numerous awards, including the National Institute of Health T32, LRP and KL2 career development awards, which led to clinical and translational research expertise in hepatocellular carcinoma (HCC). I lead the multidisciplinary Hepatocellular Carcinoma (HCC) clinic that focuses on the clinical management and research of patients with HCC. The clinic serves as a platform for translational research and clinical trials. Additionally, I am a recipient of several awards for excellence in patient care or satisfaction and exemplary teaching.
My research interests include clinical/translational research in hepatocellular carcinoma (HCC). Specifically, I study immunopathogenesis of hepatitis C-related cirrhosis and HCC. I am the author of 60 peer-reviewed publications, 29 abstracts submitted at national and international meetings and 11 book chapters. I am the Primary Investigator (PI) on six externally funded grants, totaling over half a million, and also the PI for several industry-sponsored studies and clinical trials.
Teaching Profile
Courses Taught
2018
MDC6001 Intro Clin Practice
Board Certifications
-
GastroenterologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Gastroenterology
Subspecialties
- Transplant Hepatology
Areas of Interest
- Autoimmune hepatitis
- Cirrhosis
- Gastrointestinal cancer
- Hepatitis B
- Hepatitis C
- Liver Transplant
- Liver biopsy
- Liver cancer – hepatocellular carcinoma
- Liver disease
- Primary biliary cirrhosis
Publications
2023
Adherence to guideline-directed hepatocellular carcinoma screening: A single-center US experience.
World journal of hepatology.
15(3):410-418
[DOI] 10.4254/wjh.v15.i3.410.
[PMID] 37034234.
2023
Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States.
Preventive medicine reports.
32
[DOI] 10.1016/j.pmedr.2023.102138.
[PMID] 36865395.
2023
Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis.
Journal of hepatocellular carcinoma.
10:1129-1141
[DOI] 10.2147/JHC.S417273.
[PMID] 37489126.
2023
Laparoscopic ultrasonography of the liver is feasible and safe in dogs.
American journal of veterinary research.
84(11)
[DOI] 10.2460/ajvr.23.05.0088.
[PMID] 37619615.
2022
Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.
Hepatology (Baltimore, Md.).
75(5):1289-1299
[DOI] 10.1002/hep.32240.
[PMID] 34778999.
2021
A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.
Gastroenterology research.
14(3):139-156
[DOI] 10.14740/gr1405.
[PMID] 34267829.
2021
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC.
Hepatology communications.
5(3):538-547
[DOI] 10.1002/hep4.1652.
[PMID] 33681685.
2021
Advances in the management of cholangiocarcinoma.
World journal of hepatology.
13(9):1003-1018
[DOI] 10.4254/wjh.v13.i9.1003.
[PMID] 34630871.
2021
Do patients at high risk for Hepatitis C receive recommended testing? A retrospective cohort study of statewide Medicaid claims linked with OneFlorida clinical data.
Medicine.
100(50)
[DOI] 10.1097/MD.0000000000028316.
[PMID] 34918711.
2021
Favorable Survival with Non-curative Treatments for Patients with Early-Stage Hepatocellular Carcinoma After Liver Transplant Denial.
Digestive diseases and sciences.
66(2):628-635
[DOI] 10.1007/s10620-020-06201-w.
[PMID] 32219612.
2021
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
European journal of gastroenterology & hepatology.
33(1):102-106
[DOI] 10.1097/MEG.0000000000001700.
[PMID] 32243349.
2020
Down staging of hepatocellular carcinoma-can we push the boundaries?
Hepatobiliary surgery and nutrition.
9(4):540-542
[DOI] 10.21037/hbsn.2019.11.14.
[PMID] 32832514.
2020
Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation
American Journal of Clinical Oncology-Cancer Clinical Trials.
43(5):325-333
[DOI] 10.1097/COC.0000000000000678.
[PMID] 32079854.
2019
Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis.
HPB : the official journal of the International Hepato Pancreato Biliary Association.
21(2):249-257
[DOI] 10.1016/j.hpb.2018.07.004.
[PMID] 30057124.
2019
Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation.
BioMed research international.
2019
[DOI] 10.1155/2019/7284040.
[PMID] 31737675.
2018
Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma.
Abdominal radiology (New York).
43(7):1825-1836
[DOI] 10.1007/s00261-017-1354-6.
[PMID] 29052747.
2018
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Journal of hepatology.
69(2):353-358
[DOI] 10.1016/j.jhep.2018.04.010.
[PMID] 29704513.
2018
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
Journal of gastrointestinal cancer.
49(2):107-115
[DOI] 10.1007/s12029-018-0065-8.
[PMID] 29453759.
2017
Intractable Fasting Hypoglycemia as a Manifestation of Hepatocellular Carcinoma.
Case reports in hepatology.
2017
[DOI] 10.1155/2017/7465025.
[PMID] 28785493.
2017
Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chembolization for the Treatment of Hepatocellular Carcinoma.
Current problems in diagnostic radiology.
46(6):402-409
[DOI] 10.1067/j.cpradiol.2017.02.006.
[PMID] 28392205.
2017
Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma.
Clinics in liver disease.
21(2):231-251
[DOI] 10.1016/j.cld.2016.12.002.
[PMID] 28364811.
2015
Current and future treatments for hepatocellular carcinoma.
World journal of gastroenterology.
21(28):8478-91
[DOI] 10.3748/wjg.v21.i28.8478.
[PMID] 26229392.
2015
Transportal Radioembolization as Salvage Hepatocellular Carcinoma Therapy to Maintain Liver Transplant Candidacy.
Journal of vascular and interventional radiology : JVIR.
26(10):1479-83
[DOI] 10.1016/j.jvir.2015.06.029.
[PMID] 26408214.
2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Liver international : official journal of the International Association for the Study of the Liver.
34(9):1428-44
[DOI] 10.1111/liv.12541.
[PMID] 24661807.
2013
Another armed CD4(+) T cell ready to battle hepatocellular carcinoma.
Hepatology (Baltimore, Md.).
58(1):1-3
[DOI] 10.1002/hep.26377.
[PMID] 23475554.
2013
CC genotype donors for the interleukin-28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant.
Liver international : official journal of the International Association for the Study of the Liver.
33(1):72-8
[DOI] 10.1111/liv.12013.
[PMID] 23107586.
2013
Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation.
Digestive diseases and sciences.
58(5):1403-9
[DOI] 10.1007/s10620-012-2521-9.
[PMID] 23306846.
2013
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Cancer immunology, immunotherapy : CII.
62(4):737-46
[DOI] 10.1007/s00262-012-1380-8.
[PMID] 23223899.
2013
Management of liver cirrhosis in patients with hepatocellular carcinoma.
Chinese clinical oncology.
2(4)
[DOI] 10.3978/j.issn.2304-3865.2013.09.03.
[PMID] 25841913.
2013
Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma.
Hepatology research : the official journal of the Japan Society of Hepatology.
43(7):757-64
[DOI] 10.1111/hepr.12019.
[PMID] 23193965.
2013
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Laboratory investigation; a journal of technical methods and pathology.
93(1):8-19
[DOI] 10.1038/labinvest.2012.144.
[PMID] 23108376.
2013
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
37(1):91-7
[DOI] 10.1111/apt.12098.
[PMID] 23094860.
2013
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma.
Oncology reports.
29(4):1259-67
[DOI] 10.3892/or.2013.2290.
[PMID] 23426976.
2012
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics.
Hepatic medicine : evidence and research.
4:19-37
[DOI] 10.2147/HMER.S16316.
[PMID] 24367230.
2012
Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
American journal of clinical oncology.
35(4):345-50
[DOI] 10.1097/COC.0b013e31821631f6.
[PMID] 21552101.
2012
Incidentally Discovered Hcc (Ihcc) in Explant Liver- Clinical and Histopathologic Features and Outcome
Higher Education Policy.
56:476A-477A
2012
Rare case of adult undifferentiated (embryonal) sarcoma of the liver treated with liver transplantation: excellent long-term survival.
Case reports in hepatology.
2012
[DOI] 10.1155/2012/519741.
[PMID] 25374706.
2012
Serum Levels of Soluble Cd25 as a Marker for Hepatocellular Carcinoma
Oncology letters.
4(4):840-846
[DOI] 10.3892/ol.2012.826.
[PMID] 23205111.
2012
Systemic targeted therapy beyond sorafenib.
Clinical liver disease.
1(6):212-216
[DOI] 10.1002/cld.128.
[PMID] 31186890.
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy.
56:458A-459A
2012
The Impact of Pre Transplant Transarterial Therapy in Hepatocellular Carcinoma
Higher Education Policy.
56:458A-459A
2011
A Sustained Viral Response Dramatically Improves Survival in Patients With Hepatitis C Infection After Liver Transplant
.
54
2011
Antiviral Effect of Sorafenib in Hcv Related Hepatocellular Carcinoma
Higher Education Policy.
54
2011
Boceprevir for chronic HCV genotype 1 infection.
The New England journal of medicine.
365(2):176; author reply 177-8
[DOI] 10.1056/NEJMc1105515.
[PMID] 21751914.
2011
Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro.
International journal of radiation biology.
87(1):71-80
[DOI] 10.3109/09553002.2010.518208.
[PMID] 20958220.
2011
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Laboratory investigation; a journal of technical methods and pathology.
91(4):598-608
[DOI] 10.1038/labinvest.2010.205.
[PMID] 21321535.
2011
Klatskin Tumor- Clinical Outcome and Prognostic Factors
Higher Education Policy.
54
2011
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.
Alimentary pharmacology & therapeutics.
33(2):235-42
[DOI] 10.1111/j.1365-2036.2010.04512.x.
[PMID] 21083674.
2011
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
34(2):205-13
[DOI] 10.1111/j.1365-2036.2011.04697.x.
[PMID] 21605146.
2010
Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25).
Digestive diseases and sciences.
55(2):484-95
[DOI] 10.1007/s10620-009-0955-5.
[PMID] 19714465.
2010
Imaging of hepatocellular carcinoma and early diagnosis.
Minerva medica.
101(6):395-404
[PMID] 21196899.
2010
Incidence of Hepatocellular Carcinoma in Florida: Distribution in Racial Subpopulations
Higher Education Policy.
52
2010
Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma.
Scandinavian journal of immunology.
72(4):293-301
[DOI] 10.1111/j.1365-3083.2010.02427.x.
[PMID] 20883314.
2010
Review article: the management of hepatocellular carcinoma.
Alimentary pharmacology & therapeutics.
31(4):461-76
[DOI] 10.1111/j.1365-2036.2009.04200.x.
[PMID] 19925500.
2010
The Impact of Preservation Injury On Accelerated Hepatitis C Recurrence After Liver Transplantation
Higher Education Policy.
52
2010
The Impact of Transarterial Therapy in Recurrent Hepatocellular Carcinoma After Liver Transplant
Higher Education Policy.
52
2010
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Digestive diseases and sciences.
55(1):196-203
[DOI] 10.1007/s10620-009-0981-3.
[PMID] 19798576.
2009
Fenofibrate Improves Liver Biochemistries in Primary Biliary Cirrhosis
Higher Education Policy.
50
2009
Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells.
Cell biology international.
33(5):565-71
[DOI] 10.1016/j.cellbi.2009.02.007.
[PMID] 19268553.
2009
Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation.
PloS one.
4(11)
[DOI] 10.1371/journal.pone.0007980.
[PMID] 19956753.
2009
The natural history of hepatitis C cirrhosis after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
15(9):1063-71
[DOI] 10.1002/lt.21784.
[PMID] 19718647.
2009
Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
15(2):216-22
[DOI] 10.1002/lt.21666.
[PMID] 19177434.
2008
Cyclosporine Helps To Achieve a Higher Svr in Patients Receiving Peg-Interferon/Ribavirin for Recurrent Hepatitis C After Liver Transplantation: Final Analysis of a Randomized-Controlled Study
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60197-X.
2008
Hepatocellular Carcinoma Is Associated With An Impaired Cd4 T Cell Immune Response
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60360-8.
2008
Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients With Hepatitis C
American Journal of Transplantation.
8
2008
The Natural History of Hcv-Related Cirrhosis After Liver Transplantation
Journal of Hepatology.
48
[DOI] 10.1016/S0168-8278(08)60003-3.
2008
Using Immune Functional Assay To Differentiate Acute Cellular Rejection From Recurrent Hepatitis C in Liver Transplant Patients
Higher Education Policy.
48
2007
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.
Laboratory investigation; a journal of technical methods and pathology.
87(6):582-90
[PMID] 17372588.
2007
New Inhibitors of the HCV Life Cycle
Hot Topics in Viral Hepatitis.
7-13
2007
The “C” of viral hepatitis in children.
Seminars in liver disease.
27(3):295-311
[PMID] 17682976.
2006
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
12(1):51-7
[PMID] 16382464.
2004
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection.
Hepatology (Baltimore, Md.).
40(5):1062-71
[PMID] 15486925.
2004
One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
10(10):1240-7
[PMID] 15376304.
2003
Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.
Hepatology (Baltimore, Md.).
38(4):859-68
[PMID] 14512873.
Grants
Jan 2024
ACTIVE
D419CR00035 LIVER-R An Observational Mult-Center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via ASTRAZENECA
Mar 2022
ACTIVE
Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma
Role: Principal Investigator
Funding: HELIO HEALTH
Sep 2021
ACTIVE
ALTUS: Performance of a Multi-Target Hepatocellular Carcinoma (HCC) Test in Subjects with Increased Risk
Role: Principal Investigator
Funding: EXACT SCIENCES CORPORATION
Apr 2021
– Aug 2022
An Open-Label Study of Regorafenib in Combination with Pembrolizumab in
Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after
PD-1/PD-L1 Immune Checkpoint Inhibitors
Role: Principal Investigator
Funding: IQVIA Holdings
via BAYER HEALTHCARE PHARMACEUTICALS
Sep 2020
– Aug 2021
Utilization of Phenotypic Precision Medicine to Identify Optimal Drug Combinations for the Treatment of Hepatocellular Carcinoma
Role: Co-Investigator
Funding: NATL INST OF HLTH NCATS
Jan 2020
– Dec 2023
Introducing Palliative Care (PC) within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via PATIENT-CENTERED OUTCOMES RES INST
Dec 2019
ACTIVE
Case-Control Study of the Glycotest HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Role: Principal Investigator
Funding: GLYCOTEST INC
Nov 2019
– Jul 2022
A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Role: Principal Investigator
Funding: FORTREA
via BAYER HEALTHCARE PHARMACEUTICALS
Aug 2019
– Aug 2024
Prospective Clinical Trial to Detect Liver Cancer through Quantification of cfDNA Methylation in Blood Samples (CLiMB)
Role: Principal Investigator
Funding: FORTREA
via HELIO HEALTH
Sep 2018
– Sep 2023
A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of envatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via EISAI CO
Jul 2018
– Sep 2021
An Observational Cohort Study of the Use of Avatrombopag in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure
Role: Principal Investigator
Funding: UNITED BIOSOURCE
via DOVA PHARMACEUTICALS
Jan 2018
– Jan 2023
REFINE: Regorafenib observational study in hepatocellular carcinoma
Role: Principal Investigator
Funding: BAYER HEALTHCARE
Dec 2016
ACTIVE
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Nov 2016
– Nov 2021
A phase 1/2, multicenter, open-label, dose finding study to assess the safety, tolerability, and preliminary efficacy of CC-122 in combination with nivolumab in subjects with unresectable
hepatocellular carcinoma (HCC)
Role: Principal Investigator
Funding: CELGENE CORP
Jun 2016
– Jun 2021
A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via SILLAJEN INC
Mar 2015
– Aug 2018
A PHASE 1B, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-122 IN COMBINATION WITH SORAFENIB IN SUBJECTS WITH . . .
Role: Principal Investigator
Funding: CELGENE CORP
Mar 2015
– Aug 2018
A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination with Sorafenib in Subjects with Unresectable Hepatocellular Carcinoma
Role: Principal Investigator
Funding: CELGENE CORP
Oct 2014
ACTIVE
214 OPERATING ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Apr 2014
– Apr 2019
PHASE 3,RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF CABOZANTINIB (XL184) VS PLACEBO IN SUBJECTS WITH …..
Role: Principal Investigator
Funding: EXELIXIS
Apr 2014
– Jul 2018
Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib'
Role: Principal Investigator
Funding: EXELIXIS
Feb 2013
– Feb 2019
Bayer 15982 'A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib'
Role: Principal Investigator
Funding: BAYER HEALTHCARE PHARMACEUTICALS
Nov 2012
– Nov 2018
'A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy'
Role: Principal Investigator
Funding: DAIICHI PHARMACEUTICAL PHARM CORP
Education
Fellowship – Gastroenterology
2006
·
University of Florida
Residency – Internal Medicine
2002
·
University of Florida
Medical Degree
2000
·
Howard University
Contact Details
Phones:
- Business:
- (352) 273-9400
Emails:
- Business:
- rcabrera@ufl.edu
Addresses:
- Business Mailing:
-
DIVISION OF GASTROENTEROLOGY AND HEPATOLOGY
PO BOX 100246
DEPARTMENT OF MEDICINE
GAINESVILLE FL 326100246 - Business Street:
-
PO Box 100214
GAINESVILLE FL 32610